Clinical Trials

91 enrolled

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT05888493 2026-02-20

LEDA

109 enrolled

Phase 1 Not yet recruiting

Lymphoma, Follicular, Recurrence

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

180 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

438 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT04094311 2026-02-17

Study of Out of Specification for Tisagenlecleucel

Phase 3 Recruiting

200 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05079282 2026-02-13

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

217 enrolled

Phase 2 Active not recruiting

Recurrence, Lymphoma, T-Cell

NCT05144841 2026-02-13

MK-2140-004

140 enrolled

Phase 1 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04690595 2026-02-11

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

24 enrolled

Burkitt Lymphoma, Recurrence

NCT06522737 2026-02-11

TERZO

Phase 3 Recruiting

124 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT06542250 2026-02-10

TITANium

174 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Phase 2 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

50 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

48 enrolled

Phase 3 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT04809467 2026-02-04

topMIND

Phase 1/2 Terminated

54 enrolled 23 charts

Phase 1 Active not recruiting

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06854653 2026-02-03

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

115 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02651662 2026-02-02

CLIO-1

105 enrolled

Recurrence, Lymphoma, B-Cell

NCT06909877 2026-01-30

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

100 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07134088 2026-01-29

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05753501 2026-01-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

340 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT04139434 2026-01-23

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Phase 1 Completed

32 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Phase 2 Completed

48 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06022029 2025-12-24

ON-5001